About Caplin Point Laboratories Limited
Data last updated: 14 July 2026
Caplin Point Laboratories Limited is a public limited company based in Chennai, Tamil Nadu, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 16 April 1990, the company has been in operation for over 36 years.
Registered with ROC Chennai under CIN L24231TN1990PLC019053. Listed on BSE: 524742 and NSE: CAPLIPOINT.
Capital: an authorised share capital of ₹17 Cr and a paid-up capital of ₹15.2 Cr. Formerly known as Caplin Point Laboratories Private Limited. It is led by directors including Komattu Chacko John and Paarthipan Chingelput Chellappan.
Last AGM: 22 September 2025. Financial statements filed for year ended 31 March 2025. Office: Chennai, Tamil Nadu.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹2,187.19 Cr, a growth of 12.89% compared to the previous year. The net worth stands at ₹3,630.8 Cr (up 25.79% YoY). Total assets are valued at ₹4,045.48 Cr (up 26.08% YoY).
The company has a workforce of approximately 987 employees as per the latest available data. Its group structure includes 2 subsidiaries.
The company is associated with 2 brands - Amaris Clinical, Caplin Point Laboratories. As per MCA filings, the company has open charges of ₹10 Lakh and satisfied charges of ₹102.92 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website caplinpoint.net.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressAshvich Towers 3Rd Floor No.3 Developed Plots Industrial Estates Per, Ungudi, Chennai, Tamil Nadu, India – 600096
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has one previous CIN (Corporate Identification Number): L24231TN1990PTC019053. The current CIN is L24231TN1990PLC019053, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231TN1990PLC019053 | Current |
| L24231TN1990PTC019053 | Previous |
Associated Brands with Caplin Point Laboratories Limited
Caplin Point Laboratories Limited operates two associated brands: Amaris Clinical and Caplin Point laboratories. These brands represent Caplin Point Laboratories Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of a pharmaceutical generics and biotech products | caplinpoint.net | |
| Clinical research, bioanalysis, and technical services are offered by Amaris Clinical. | amarisclinical.com |
Business Activity of Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Caplin Point Laboratories Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is audited by Brahmayya & Co. (ICAI peer reviewed, certificate valid till 2027-04-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Brahmayya & Co. (ICAI peer reviewed, certificate valid till 2027-04-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is currently managed by 9 directors, with 21 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Komattu Chacko John
Also directs:
Caplin Steriles Limited
|
Additional Director | 05 Nov 2025 | 0 Years 9 Months | Current |
|
Paarthipan Chingelput Chellappan
Also directs:
Caplin Steriles Limited, Caplin One Labs Limited, Indo-Latin American Chamber Of Commerce & Industry Private Limited and 1 more
|
Director | 01 Oct 1993 | 32 Years 10 Months | Current |
| Sridhar Ganesan | Managing Director | 12 Feb 2014 | 12 Years 6 Months | Current |
|
Ramachandramurthy Nagendran
Also directs:
Sriman Madhwa Sidhantaonnahini Permanent Nidhi Limited
|
Director | 29 Sep 2022 | 3 Years 10 Months | Current |
|
Singaram Deenadayalan
Also directs:
Caplin One Labs Limited, Truscomp Private Limited, Ceo Skill Foundations Private Limited and 1 more
|
Director | 29 Sep 2022 | 3 Years 10 Months | Current |
| Ashok Gorkey Partheeban | Additional Director | 05 Nov 2025 | 0 Years 9 Months | Current |
Financials of Caplin Point Laboratories Limited FY 2026 filings available
Caplin Point Laboratories Limited reported revenue of ₹2,187.19 Cr (up 12.89% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹2,187.19 Cr | ₹1,937.47 Cr | ₹1,694.1 Cr | ₹1,466.73 Cr | ₹1,269.41 Cr | ₹1,061.29 Cr | ₹863.2 Cr |
| Other Income | ₹115.54 Cr | ₹96.43 Cr | ₹66.94 Cr | ₹55.98 Cr | ₹38.75 Cr | ₹23.54 Cr | ₹41.33 Cr |
| Total Income | ₹2,302.73 Cr | ₹2,033.9 Cr | ₹1,761.04 Cr | ₹1,522.71 Cr | ₹1,308.16 Cr | ₹1,084.83 Cr | ₹904.54 Cr |
| Cost of Materials Consumed | ₹357.2 Cr | ₹248.45 Cr | ₹239.81 Cr | ₹223.04 Cr | ₹192.31 Cr | ₹129.82 Cr | ₹108.12 Cr |
| Purchases of Stock-in-Trade | ₹572.2 Cr | ₹575.7 Cr | ₹558.92 Cr | ₹519.03 Cr | ₹397.13 Cr | ₹259.57 Cr | ₹500.14 Cr |
| Changes in Inventories | -₹63.72 Cr | -₹53.31 Cr | -₹74.55 Cr | -₹78.86 Cr | -₹31.93 Cr | ₹82.35 Cr | -₹195.1 Cr |
| Employee Benefit Expense | ₹199.15 Cr | ₹177.72 Cr | ₹143.59 Cr | ₹136.99 Cr | ₹115.3 Cr | ₹102.53 Cr | ₹67.76 Cr |
| Finance Costs | ₹87 Lakh | ₹61 Lakh | ₹78 Lakh | ₹78 Lakh | ₹70 Lakh | ₹1.59 Cr | ₹31.97 Lakh |
| Depreciation & Amortisation | ₹72.77 Cr | ₹65.96 Cr | ₹53.44 Cr | ₹44.99 Cr | ₹46.9 Cr | ₹36.97 Cr | ₹31.62 Cr |
| Other Expenses | ₹361.51 Cr | ₹341.98 Cr | ₹274.89 Cr | ₹225.47 Cr | ₹201.93 Cr | ₹158.38 Cr | ₹122.21 Cr |
| Total Expenses | ₹1,499.98 Cr | ₹1,357.11 Cr | ₹1,196.88 Cr | ₹1,071.44 Cr | ₹922.34 Cr | ₹771.21 Cr | ₹635.07 Cr |
| Profit Before Exceptional Items & Tax | ₹802.75 Cr | ₹676.79 Cr | ₹564.16 Cr | ₹451.27 Cr | ₹385.82 Cr | ₹313.62 Cr | ₹269.46 Cr |
| Exceptional Items | ₹4 Lakh | ₹0 | ₹27 Lakh | ₹8 Lakh | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹802.79 Cr | ₹676.79 Cr | ₹564.43 Cr | ₹451.35 Cr | ₹385.82 Cr | ₹313.62 Cr | ₹269.46 Cr |
| Total Tax Expense | ₹153.06 Cr | ₹135.69 Cr | ₹103.01 Cr | ₹74.36 Cr | ₹77.37 Cr | ₹62.18 Cr | ₹54.38 Cr |
| Net Profit | ₹649.73 Cr | ₹541.09 Cr | ₹461.42 Cr | ₹376.99 Cr | ₹308.45 Cr | ₹251.44 Cr | ₹215.08 Cr |
| attributable to Owners | ₹641.24 Cr | ₹563.38 Cr | ₹457.08 Cr | ₹376.26 Cr | - | ₹242.28 Cr | ₹215.01 Cr |
| attributable to NCI | ₹8.49 Cr | ₹4.78 Cr | ₹4.33 Cr | ₹73 Lakh | - | ₹9.16 Cr | ₹7.57 Lakh |
| Other Comprehensive Income | ₹141.64 Cr | ₹27.07 Cr | ₹11.45 Cr | ₹42.75 Cr | ₹14.26 Cr | -₹7.16 Cr | ₹16.67 Cr |
| Total Comprehensive Income | ₹791.37 Cr | ₹568.16 Cr | ₹472.87 Cr | ₹419.74 Cr | ₹322.71 Cr | ₹244.28 Cr | ₹231.75 Cr |
| EBITDA (computed) | ₹876.39 Cr | ₹743.36 Cr | ₹618.38 Cr | ₹497.04 Cr | ₹433.42 Cr | ₹352.18 Cr | ₹301.4 Cr |
| Basic EPS | ₹84.36 | ₹70.57 | ₹60.19 | ₹49.62 | ₹39.61 | ₹32.03 | ₹28.42 |
| Diluted EPS | ₹84.11 | ₹70.25 | ₹59.90 | ₹49.18 | ₹39.26 | ₹31.71 | ₹28.20 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹4,045.48 Cr | ₹3,208.58 Cr | ₹2,697.37 Cr | ₹2,191.4 Cr |
| Non-current Assets | ₹1,459.82 Cr | ₹1,074.63 Cr | ₹805.16 Cr | ₹636.94 Cr |
| Current Assets | ₹2,585.66 Cr | ₹2,133.95 Cr | ₹1,892.21 Cr | ₹1,554.46 Cr |
| Property, Plant & Equipment | ₹547.49 Cr | ₹530.32 Cr | ₹438.62 Cr | ₹267.01 Cr |
| Inventories | ₹428.86 Cr | ₹336.1 Cr | ₹363.04 Cr | ₹288.22 Cr |
| Trade Receivables | ₹825.81 Cr | ₹632.49 Cr | ₹542.72 Cr | ₹394.06 Cr |
| Cash & Equivalents | ₹94.18 Cr | ₹199.45 Cr | ₹138.7 Cr | ₹177.56 Cr |
| Equity (Net Worth) | ₹3,630.8 Cr | ₹2,886.39 Cr | ₹2,346.82 Cr | ₹1,907.27 Cr |
| Equity Share Capital | ₹15.2 Cr | ₹15.2 Cr | ₹15.19 Cr | ₹15.18 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹92 Lakh | ₹0 |
| Borrowings (Current) | ₹57 Lakh | ₹55 Lakh | ₹28 Lakh | ₹3.41 Cr |
| Total Debt (computed) | ₹57 Lakh | ₹55 Lakh | ₹1.2 Cr | ₹3.41 Cr |
| Current Liabilities | ₹385.94 Cr | ₹306.38 Cr | ₹330.55 Cr | ₹268 Cr |
| Total Liabilities | ₹414.68 Cr | ₹322.19 Cr | ₹350.55 Cr | ₹284.13 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹523.23 Cr | ₹432.37 Cr | ₹310.98 Cr | ₹271.65 Cr | ₹336.75 Cr |
| Investing Cash Flow | -₹582.29 Cr | -₹334.73 Cr | -₹312.63 Cr | -₹217.86 Cr | -₹270.94 Cr |
| Financing Cash Flow | -₹46.46 Cr | -₹38.32 Cr | -₹38.07 Cr | -₹28.17 Cr | -₹40.71 Cr |
| Capital Expenditure | ₹248.13 Cr | ₹191.52 Cr | ₹145.81 Cr | ₹193.75 Cr | ₹91.18 Cr |
| Free Cash Flow (computed) | ₹275.1 Cr | ₹240.85 Cr | ₹165.17 Cr | ₹77.9 Cr | ₹245.57 Cr |
| Dividends Paid | ₹45.61 Cr | ₹37.99 Cr | ₹34.17 Cr | ₹30.32 Cr | ₹22.69 Cr |
| Net Change in Cash | -₹105.27 Cr | ₹59.32 Cr | -₹38.86 Cr | ₹26.8 Cr | ₹25.01 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹600.16 Cr | ₹542.77 Cr | ₹534.04 Cr | ₹510.22 Cr | ₹502.45 Cr | ₹492.96 Cr | ₹483.1 Cr | ₹458.96 Cr | ₹453.22 Cr | ₹435.5 Cr | ₹410.06 Cr | ₹395.32 Cr |
| Other Income | ₹28.36 Cr | ₹33.68 Cr | ₹30.37 Cr | ₹23.14 Cr | ₹25.74 Cr | ₹31.36 Cr | ₹20.77 Cr | ₹18.56 Cr | ₹17.29 Cr | ₹17.18 Cr | ₹20.43 Cr | ₹12.04 Cr |
| Total Income | ₹628.52 Cr | ₹576.45 Cr | ₹564.41 Cr | ₹533.36 Cr | ₹528.19 Cr | ₹524.32 Cr | ₹503.87 Cr | ₹477.52 Cr | ₹470.51 Cr | ₹452.68 Cr | ₹430.49 Cr | ₹407.36 Cr |
| Cost of Materials Consumed | ₹102.11 Cr | ₹89.24 Cr | ₹92.34 Cr | ₹73.51 Cr | ₹60.84 Cr | ₹59.8 Cr | ₹69.23 Cr | ₹63.65 Cr | ₹57.87 Cr | ₹50.96 Cr | ₹66.85 Cr | ₹64.14 Cr |
| Purchases of Stock-in-Trade | ₹209.02 Cr | ₹128 Cr | ₹121.68 Cr | ₹113.5 Cr | ₹138.77 Cr | ₹139.43 Cr | ₹122.33 Cr | ₹74.48 Cr | ₹121.78 Cr | ₹179.77 Cr | ₹129.33 Cr | ₹128.04 Cr |
| Changes in Inventories | -₹66.13 Cr | -₹2.1 Cr | -₹3.72 Cr | ₹8.23 Cr | ₹1.59 Cr | -₹3.88 Cr | -₹2.74 Cr | ₹47.35 Cr | ₹11.72 Cr | -₹40.61 Cr | -₹32.08 Cr | -₹13.58 Cr |
| Employee Benefit Expense | ₹52.62 Cr | ₹49.78 Cr | ₹47.23 Cr | ₹43.16 Cr | ₹46.51 Cr | ₹46.77 Cr | ₹44.29 Cr | ₹40.15 Cr | ₹36.77 Cr | ₹36.67 Cr | ₹35.08 Cr | ₹35.07 Cr |
| Finance Costs | ₹36 Lakh | ₹18 Lakh | ₹16 Lakh | ₹18 Lakh | ₹17 Lakh | ₹18 Lakh | ₹21 Lakh | ₹5 Lakh | ₹15 Lakh | ₹17 Lakh | ₹17.8 Lakh | ₹28 Lakh |
| Depreciation & Amortisation | ₹18.8 Cr | ₹19.28 Cr | ₹18.4 Cr | ₹16.29 Cr | ₹17.04 Cr | ₹16.2 Cr | ₹16.76 Cr | ₹15.96 Cr | ₹16.4 Cr | ₹13.9 Cr | ₹11.77 Cr | ₹11.38 Cr |
| Other Expenses | ₹98.3 Cr | ₹88.16 Cr | ₹87.34 Cr | ₹94.06 Cr | ₹86.68 Cr | ₹88.55 Cr | ₹85.23 Cr | ₹81.52 Cr | ₹79.85 Cr | ₹66.44 Cr | ₹73.48 Cr | ₹55.04 Cr |
| Total Expenses | ₹415.08 Cr | ₹372.54 Cr | ₹363.43 Cr | ₹348.93 Cr | ₹351.6 Cr | ₹347.05 Cr | ₹335.31 Cr | ₹323.16 Cr | ₹324.54 Cr | ₹307.3 Cr | ₹284.6 Cr | ₹280.37 Cr |
| Profit Before Exceptional Items & Tax | ₹213.44 Cr | ₹203.91 Cr | ₹200.98 Cr | ₹184.43 Cr | ₹176.59 Cr | ₹177.27 Cr | ₹168.56 Cr | ₹154.36 Cr | ₹145.97 Cr | ₹145.38 Cr | ₹145.89 Cr | ₹126.99 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹6 Lakh | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹213.44 Cr | ₹203.91 Cr | ₹200.98 Cr | ₹184.43 Cr | ₹176.59 Cr | ₹177.27 Cr | ₹168.56 Cr | ₹154.36 Cr | ₹146.03 Cr | ₹145.38 Cr | ₹145.89 Cr | ₹126.99 Cr |
| Total Tax Expense | ₹40.56 Cr | ₹38.03 Cr | ₹40.77 Cr | ₹33.7 Cr | ₹31.39 Cr | ₹37.19 Cr | ₹37.65 Cr | ₹29.46 Cr | ₹24.8 Cr | ₹25.58 Cr | ₹29.86 Cr | ₹22.76 Cr |
| Net Profit | ₹172.88 Cr | ₹165.86 Cr | ₹160.23 Cr | ₹150.76 Cr | ₹145.28 Cr | ₹140.07 Cr | ₹130.81 Cr | ₹124.92 Cr | ₹121.23 Cr | ₹119.83 Cr | ₹116.15 Cr | ₹104.23 Cr |
| attributable to Owners | ₹170.11 Cr | ₹163.88 Cr | ₹154.45 Cr | ₹152.8 Cr | ₹140.82 Cr | ₹138.96 Cr | ₹130.8 Cr | ₹123.97 Cr | ₹121.59 Cr | ₹117.2 Cr | ₹114.87 Cr | ₹103.43 Cr |
| attributable to NCI | ₹2.77 Cr | ₹1.98 Cr | ₹5.78 Cr | -₹2.04 Cr | ₹2.71 Cr | ₹1.11 Cr | ₹1 Lakh | ₹95 Lakh | -₹36 Lakh | ₹2.62 Cr | ₹1.27 Cr | ₹80 Lakh |
| Other Comprehensive Income | ₹76.9 Cr | ₹16.84 Cr | ₹47.54 Cr | ₹36 Lakh | -₹1.75 Cr | ₹22.81 Cr | ₹1.33 Cr | ₹4.68 Cr | ₹3.26 Cr | ₹86.6 Lakh | ₹9.67 Cr | -₹2.33 Cr |
| Total Comprehensive Income | ₹249.78 Cr | ₹182.7 Cr | ₹207.77 Cr | ₹151.12 Cr | ₹143.53 Cr | ₹162.88 Cr | ₹132.14 Cr | ₹129.6 Cr | ₹124.49 Cr | ₹120.69 Cr | ₹125.81 Cr | ₹101.9 Cr |
| EBITDA (computed) | ₹232.6 Cr | ₹223.37 Cr | ₹219.54 Cr | ₹200.9 Cr | ₹193.8 Cr | ₹193.65 Cr | ₹185.53 Cr | ₹170.37 Cr | ₹162.52 Cr | ₹159.45 Cr | ₹157.83 Cr | ₹138.65 Cr |
| Basic EPS | ₹22.38 | ₹21.56 | ₹20.32 | ₹20.10 | ₹18.75 | ₹18.28 | ₹17.22 | ₹16.32 | ₹16.01 | ₹15.44 | ₹15.13 | ₹13.62 |
| Diluted EPS | ₹22.31 | ₹21.51 | ₹20.25 | ₹20.03 | ₹18.69 | ₹18.19 | ₹17.12 | ₹16.24 | ₹15.90 | ₹15.39 | ₹15.06 | ₹13.55 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Rest of the World | ₹470.25 Cr | ₹163.32 Cr | ₹1,918.28 Cr | ₹332.52 Cr |
| USA | ₹129.91 Cr | ₹21.76 Cr | ₹656 Cr | ₹82.16 Cr |
| Unallocated | ₹28.36 Cr | ₹28.36 Cr | ₹1,471.2 Cr | ₹0 |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Rest of the World | ₹1,733.79 Cr | ₹631.2 Cr | - | - |
| USA | ₹453.4 Cr | ₹56.05 Cr | - | - |
| Unallocated | ₹115.54 Cr | ₹115.54 Cr | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹738.33 Cr | ₹752.41 Cr | ₹625.09 Cr | ₹528.61 Cr | ₹528.06 Cr | ₹482.68 Cr | ₹527.83 Cr |
| Other Income | ₹195.37 Cr | ₹134.59 Cr | ₹105.84 Cr | ₹99 Cr | ₹56.55 Cr | ₹18.62 Cr | ₹65.97 Cr |
| Total Income | ₹933.7 Cr | ₹887 Cr | ₹730.93 Cr | ₹627.61 Cr | ₹584.61 Cr | ₹501.3 Cr | ₹593.8 Cr |
| Cost of Materials Consumed | ₹158.82 Cr | ₹136.64 Cr | ₹172.13 Cr | ₹151.35 Cr | ₹156.01 Cr | ₹112.48 Cr | ₹95.73 Cr |
| Purchases of Stock-in-Trade | ₹82.51 Cr | ₹77.17 Cr | ₹76.77 Cr | ₹48.38 Cr | ₹57.64 Cr | ₹82.92 Cr | ₹143.18 Cr |
| Changes in Inventories | -₹12.37 Cr | ₹24.36 Cr | -₹43.68 Cr | -₹1.67 Cr | -₹9 Cr | -₹57 Lakh | -₹74.1 Lakh |
| Employee Benefit Expense | ₹47.72 Cr | ₹52.13 Cr | ₹38.11 Cr | ₹36.68 Cr | ₹30.47 Cr | ₹26.59 Cr | ₹25 Cr |
| Finance Costs | ₹20 Lakh | ₹12 Lakh | ₹10 Lakh | ₹12 Lakh | ₹9 Lakh | ₹17 Lakh | ₹18.5 Lakh |
| Depreciation & Amortisation | ₹25.43 Cr | ₹24.77 Cr | ₹27.08 Cr | ₹25.65 Cr | ₹25.77 Cr | ₹22.44 Cr | ₹19.65 Cr |
| Other Expenses | ₹123.87 Cr | ₹130.14 Cr | ₹94.68 Cr | ₹73.95 Cr | ₹73.32 Cr | ₹47.33 Cr | ₹57.66 Cr |
| Total Expenses | ₹426.18 Cr | ₹445.33 Cr | ₹365.19 Cr | ₹334.46 Cr | ₹334.3 Cr | ₹291.36 Cr | ₹340.67 Cr |
| Profit Before Exceptional Items & Tax | ₹507.52 Cr | ₹441.67 Cr | ₹365.74 Cr | ₹293.15 Cr | ₹250.31 Cr | ₹209.94 Cr | ₹253.12 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹507.52 Cr | ₹441.67 Cr | ₹365.74 Cr | ₹293.15 Cr | ₹250.31 Cr | ₹209.94 Cr | ₹253.12 Cr |
| Total Tax Expense | ₹110.94 Cr | ₹102.18 Cr | ₹82.03 Cr | ₹58.89 Cr | ₹62.44 Cr | ₹53.71 Cr | ₹55.49 Cr |
| Net Profit | ₹396.58 Cr | ₹339.49 Cr | ₹283.71 Cr | ₹234.26 Cr | ₹187.87 Cr | ₹156.23 Cr | ₹197.64 Cr |
| attributable to Owners | - | - | - | - | - | - | ₹0 |
| attributable to NCI | - | - | - | - | - | - | ₹0 |
| Other Comprehensive Income | -₹7 Lakh | -₹10 Lakh | -₹16 Lakh | ₹11 Lakh | ₹10 Lakh | ₹22 Lakh | -₹33.47 Lakh |
| Total Comprehensive Income | ₹396.51 Cr | ₹339.39 Cr | ₹283.55 Cr | ₹234.37 Cr | ₹187.97 Cr | ₹156.45 Cr | ₹197.3 Cr |
| EBITDA (computed) | ₹533.15 Cr | ₹466.56 Cr | ₹392.92 Cr | ₹318.92 Cr | ₹276.17 Cr | ₹232.55 Cr | ₹272.96 Cr |
| Basic EPS | ₹52.17 | ₹44.67 | ₹37.36 | ₹30.89 | ₹24.82 | ₹20.65 | ₹26.13 |
| Diluted EPS | ₹52.02 | ₹44.47 | ₹37.18 | ₹30.62 | ₹24.60 | ₹20.45 | ₹25.95 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹2,211.74 Cr | ₹1,814.48 Cr | ₹1,522.31 Cr | ₹1,303.18 Cr |
| Non-current Assets | ₹1,235.86 Cr | ₹988.79 Cr | ₹819.81 Cr | ₹639.2 Cr |
| Current Assets | ₹975.88 Cr | ₹825.69 Cr | ₹702.5 Cr | ₹663.98 Cr |
| Property, Plant & Equipment | ₹219.68 Cr | ₹201.59 Cr | ₹161.77 Cr | ₹151.7 Cr |
| Inventories | ₹85.66 Cr | ₹66.26 Cr | ₹86.25 Cr | ₹51.53 Cr |
| Trade Receivables | ₹265.96 Cr | ₹175.33 Cr | ₹128.67 Cr | ₹88.24 Cr |
| Cash & Equivalents | ₹44.09 Cr | ₹99.64 Cr | ₹80.64 Cr | ₹122.02 Cr |
| Equity (Net Worth) | ₹2,050.5 Cr | ₹1,700.93 Cr | ₹1,390.15 Cr | ₹1,139.91 Cr |
| Equity Share Capital | ₹15.2 Cr | ₹15.2 Cr | ₹15.19 Cr | ₹15.18 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹0 | ₹0 | ₹0 | ₹0 |
| Current Liabilities | ₹144.17 Cr | ₹99.85 Cr | ₹119.3 Cr | ₹146.85 Cr |
| Total Liabilities | ₹161.24 Cr | ₹113.55 Cr | ₹132.16 Cr | ₹163.27 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹214.78 Cr | ₹195.87 Cr | ₹104.21 Cr | ₹157.1 Cr | ₹230.97 Cr |
| Investing Cash Flow | -₹224.77 Cr | -₹140.2 Cr | -₹112.14 Cr | -₹86.67 Cr | -₹237.18 Cr |
| Financing Cash Flow | -₹45.81 Cr | -₹38.1 Cr | -₹34.26 Cr | -₹30.42 Cr | -₹22.76 Cr |
| Capital Expenditure | ₹44.63 Cr | ₹56.56 Cr | ₹23.07 Cr | ₹58.63 Cr | ₹7.22 Cr |
| Free Cash Flow (computed) | ₹170.15 Cr | ₹139.31 Cr | ₹81.14 Cr | ₹98.47 Cr | ₹223.75 Cr |
| Dividends Paid | ₹0 | ₹37.99 Cr | ₹34.17 Cr | ₹30.32 Cr | ₹22.69 Cr |
| Net Change in Cash | -₹55.55 Cr | ₹17.57 Cr | -₹41.38 Cr | ₹41.01 Cr | -₹29.06 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹191.36 Cr | ₹189.22 Cr | ₹175.18 Cr | ₹182.57 Cr | ₹173.61 Cr | ₹185.23 Cr | ₹207.93 Cr | ₹185.64 Cr | ₹139.38 Cr | ₹132.83 Cr | ₹179.22 Cr | ₹173.66 Cr |
| Other Income | ₹61.08 Cr | ₹31.73 Cr | ₹59.22 Cr | ₹32.03 Cr | ₹41.25 Cr | ₹28.83 Cr | ₹43.01 Cr | ₹21.5 Cr | ₹36.18 Cr | ₹17.9 Cr | ₹24.49 Cr | ₹27.27 Cr |
| Total Income | ₹252.44 Cr | ₹220.95 Cr | ₹234.4 Cr | ₹214.6 Cr | ₹214.86 Cr | ₹214.06 Cr | ₹250.94 Cr | ₹207.14 Cr | ₹175.56 Cr | ₹150.73 Cr | ₹203.71 Cr | ₹200.93 Cr |
| Cost of Materials Consumed | ₹45.8 Cr | ₹39.47 Cr | ₹34.92 Cr | ₹38.62 Cr | ₹34.25 Cr | ₹33.29 Cr | ₹32.72 Cr | ₹36.38 Cr | ₹40.18 Cr | ₹43.43 Cr | ₹45.84 Cr | ₹42.68 Cr |
| Purchases of Stock-in-Trade | ₹24.67 Cr | ₹23.45 Cr | ₹21.21 Cr | ₹13.18 Cr | ₹17.39 Cr | ₹19.24 Cr | ₹24.36 Cr | ₹16.18 Cr | ₹22.91 Cr | ₹13.05 Cr | ₹19.97 Cr | ₹20.84 Cr |
| Changes in Inventories | -₹14.89 Cr | -₹5.8 Cr | ₹2.05 Cr | ₹6.27 Cr | ₹3.66 Cr | ₹8.19 Cr | ₹4.7 Cr | ₹7.81 Cr | -₹19.59 Cr | -₹14.93 Cr | -₹9.37 Cr | ₹21 Lakh |
| Employee Benefit Expense | ₹13.15 Cr | ₹13.41 Cr | ₹11.54 Cr | ₹9.63 Cr | ₹14.39 Cr | ₹13.89 Cr | ₹12.99 Cr | ₹10.86 Cr | ₹9.77 Cr | ₹9.52 Cr | ₹9.1 Cr | ₹9.72 Cr |
| Finance Costs | ₹5 Lakh | ₹7 Lakh | ₹5 Lakh | ₹4 Lakh | ₹4 Lakh | ₹4 Lakh | ₹2 Lakh | ₹2 Lakh | ₹2 Lakh | ₹3 Lakh | ₹2.1 Lakh | ₹3 Lakh |
| Depreciation & Amortisation | ₹6.9 Cr | ₹6.37 Cr | ₹6.02 Cr | ₹6.14 Cr | ₹6.09 Cr | ₹6.01 Cr | ₹6.49 Cr | ₹6.18 Cr | ₹6.93 Cr | ₹6.76 Cr | ₹6.72 Cr | ₹6.67 Cr |
| Other Expenses | ₹39.04 Cr | ₹26.97 Cr | ₹29.61 Cr | ₹28.26 Cr | ₹28.88 Cr | ₹33.23 Cr | ₹35 Cr | ₹33.03 Cr | ₹28.43 Cr | ₹18.44 Cr | ₹24.23 Cr | ₹23.59 Cr |
| Total Expenses | ₹114.72 Cr | ₹103.94 Cr | ₹105.4 Cr | ₹102.14 Cr | ₹104.7 Cr | ₹113.89 Cr | ₹116.28 Cr | ₹110.46 Cr | ₹88.65 Cr | ₹76.29 Cr | ₹96.51 Cr | ₹103.74 Cr |
| Profit Before Exceptional Items & Tax | ₹137.72 Cr | ₹117.01 Cr | ₹129 Cr | ₹112.46 Cr | ₹110.16 Cr | ₹100.17 Cr | ₹134.66 Cr | ₹96.68 Cr | ₹86.91 Cr | ₹74.43 Cr | ₹107.2 Cr | ₹97.19 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹137.72 Cr | ₹117.01 Cr | ₹129 Cr | ₹112.46 Cr | ₹110.16 Cr | ₹100.17 Cr | ₹134.66 Cr | ₹96.68 Cr | ₹86.91 Cr | ₹74.43 Cr | ₹107.2 Cr | ₹97.19 Cr |
| Total Tax Expense | ₹28.22 Cr | ₹29.73 Cr | ₹26.41 Cr | ₹26.57 Cr | ₹23.66 Cr | ₹25.46 Cr | ₹28.92 Cr | ₹24.14 Cr | ₹17.03 Cr | ₹18.98 Cr | ₹25.1 Cr | ₹20.92 Cr |
| Net Profit | ₹109.5 Cr | ₹87.28 Cr | ₹102.59 Cr | ₹85.89 Cr | ₹86.5 Cr | ₹74.71 Cr | ₹105.74 Cr | ₹72.54 Cr | ₹69.88 Cr | ₹55.45 Cr | ₹82.1 Cr | ₹76.27 Cr |
| Other Comprehensive Income | -₹13 Lakh | -₹44 Lakh | ₹50 Lakh | ₹0 | -₹22 Lakh | ₹0 | ₹12 Lakh | ₹0 | -₹28 Lakh | ₹0 | ₹14 Lakh | ₹0 |
| Total Comprehensive Income | ₹109.37 Cr | ₹86.84 Cr | ₹103.09 Cr | ₹85.89 Cr | ₹86.28 Cr | ₹74.71 Cr | ₹105.86 Cr | ₹72.54 Cr | ₹69.6 Cr | ₹55.45 Cr | ₹82.24 Cr | ₹76.27 Cr |
| EBITDA (computed) | ₹144.67 Cr | ₹123.45 Cr | ₹135.07 Cr | ₹118.64 Cr | ₹116.29 Cr | ₹106.22 Cr | ₹141.17 Cr | ₹102.88 Cr | ₹93.86 Cr | ₹81.22 Cr | ₹113.94 Cr | ₹103.89 Cr |
| Basic EPS | ₹15.89 | ₹11.49 | ₹13.50 | ₹11.30 | ₹11.37 | ₹9.83 | ₹13.92 | ₹9.55 | ₹9.20 | ₹7.30 | ₹10.82 | ₹10.04 |
| Diluted EPS | ₹15.85 | ₹11.46 | ₹13.45 | ₹11.26 | ₹11.35 | ₹9.77 | ₹13.85 | ₹9.50 | ₹9.14 | ₹7.29 | ₹10.76 | ₹9.99 |
Shareholding Pattern of Caplin Point Laboratories Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 70.57%, foreign institutional investors hold 6.15%, domestic institutional investors hold 2.14%, retail and other public shareholders hold 21.14% of Caplin Point Laboratories Limited. The company had 93,896 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 70.57% | 70.57% | 70.57% | 70.56% | 70.56% | 70.56% |
| Public | 29.43% | 29.43% | 29.43% | 29.44% | 29.44% | 29.44% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 70.57% | 70.56% | 70.62% | 70.66% | 68.89% | 69.03% | 69.03% | 69.04% | 69.04% | 69.06% | 67.81% |
| Public | 29.43% | 29.44% | 29.38% | 29.34% | 31.11% | 30.97% | 30.96% | 30.96% | 30.96% | 30.94% | 32.19% |
| Promoter change (YoY, %pts) | +0.01 | -0.06 | -0.04 | +1.77 | -0.14 | +0.00 | -0.01 | +0.00 | -0.02 | +1.25 | - |
Board & Governance of Caplin Point Laboratories Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Caplin Point Laboratories Limited has 10 directors - 6 independent and 1 executive. The board is chaired by C C Paarthipan.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| C C Paarthipan | Non-Executive - Non Independent Director · Chairperson | 1993-10-01 | 1 |
| Sridhar Ganesan | Executive Director · MD | 2014-02-12 | 1 |
| C K Gariyali | Non-Executive - Independent Director | 2020-03-04 | 1 |
| R Nagendran | Non-Executive - Independent Director | 2022-09-29 | 1 |
| S Deenadayalan | Non-Executive - Independent Director | 2022-09-29 | 1 |
| Ranganathan Vijayaraghavan | Non-Executive - Independent Director | 2024-09-30 | 3 |
| Ashok Partheeban | Non-Executive - Non Independent Director | 2025-11-05 | 1 |
| K C John | Non-Executive - Independent Director | 2025-11-05 | 1 |
| Vivek Partheeban | Non-Executive - Non Independent Director | 2025-11-05 | 1 |
| Susan Mathew | Non-Executive - Independent Director | 2026-01-31 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Ranganathan Vijayaraghavan (Chairperson), R Nagendran, Sridhar Ganesan, S Deenadayalan |
| Nomination and remuneration committee | S Deenadayalan (Chairperson), C K Gariyali, C C Paarthipan, K C John |
| Stakeholders Relationship Committee | S Deenadayalan (Chairperson), Ranganathan Vijayaraghavan, Sridhar Ganesan |
| Risk Management Committee | S Deenadayalan (Chairperson), Sridhar Ganesan, D Muralidharan, Vivek Partheeban, K C John |
| Corporate Social Responsibility Committee | C C Paarthipan (Chairperson), S Deenadayalan, Sridhar Ganesan |
Group Structure of Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has 2 subsidiary companies and 1 associated company. This group structure data is as of FY 2024. The corporate group structure reflects Caplin Point Laboratories Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Caplin One Labs Limited | U24299TN2021PLC143869 | - |
| Caplin Steriles Limited | U24304TN2018PLC126270 | - |
Showing major subsidiaries. Total: 2.
Charges & Borrowings of Caplin Point Laboratories Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jan 1994 | Indian Overseas Bank | ₹10 Lakh | Open |
| 02 May 2024 | Others | ₹7.6 Cr | Satisfied |
| 28 Apr 2023 | Others | ₹10 Cr | Satisfied |
| 30 Nov 2021 | Others | ₹7.6 Cr | Satisfied |
| 23 Mar 2016 | Others | ₹80 Lakh | Satisfied |
Total charge records: 18 View all charges
Employees and EPFO Compliance at Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has a workforce of 987 employees as of Mar 29, 2025.
Employee and EPFO history for Caplin Point Laboratories Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Caplin Point Laboratories Limited
GST registrations and filing compliance for Caplin Point Laboratories Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Caplin Point Laboratories Limited
Credit ratings, litigation, and regulatory alerts for Caplin Point Laboratories Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Caplin Point Laboratories Limited
MSME payment history for Caplin Point Laboratories Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Caplin Point Laboratories Limited
Corporate group structure for Caplin Point Laboratories Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Caplin Point Laboratories Limited
MCA filings and documents for Caplin Point Laboratories Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Caplin Point Laboratories Limited
Recent News on Caplin Point Laboratories Limited
Frequently Asked Questions about Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an active public limited company in the pharma sector based in Chennai, Tamil Nadu, India. It was incorporated on 16 April 1990 (36+ years old) and is registered under CIN L24231TN1990PLC019053. Listed on BSE: 524742 and NSE: CAPLIPOINT. The company has 987 employees.
Caplin Point Laboratories Limited reported revenue of ₹2,187.19 Cr for FY 2026 (up 12.89% YoY) based on consolidated NSE filings.
The current directors of Caplin Point Laboratories Limited are:
- Komattu Chacko John - Additional Director
- Paarthipan Chingelput Chellappan - Director
- Sridhar Ganesan - Managing Director
- Ramachandramurthy Nagendran - Director
- Singaram Deenadayalan - Director
- Ashok Gorkey Partheeban - Additional Director
- Partheeban Vivek Siddarth - Additional Director
- Ranganathan Vijayaraghavan - Director
- Susan Mathew - Director
The primary industry of Caplin Point Laboratories Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Caplin Point Laboratories Limited is listed on both BSE (code: 524742) and NSE (symbol: CAPLIPOINT).
Caplin Point Laboratories Limited can be reached at the registered office: Ashvich Towers 3Rd Floor No.3 Developed Plots Industrial Estates Per, Ungudi, Chennai, Tamil Nadu, India – 600096, or through the website caplinpoint.net.